Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BARI 2D: Revascularization and Glycemic Control in Type 2 Diabetes
NCT00006305Phase 3Completed
- Sponsor
- University of Pittsburgh
- Start
- Sep 2000
- Primary completion
- Nov 2008
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of metformin and rosiglitazone in type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD) (4 arms), sponsored by University of Pittsburgh. Primary endpoint: All-Cause Mortality at 5 years. Started Sep 2000; status: completed.
02
Drugs
metforminrosiglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT00006305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006305.